Neurobiological Technologies, Inc. Presents Dosing Rationale For Viprinex(TM) (ancrod) At The European Stroke Conference
May 15th 2008Drug InformationConferences
Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII) reported for the first time at the European Stroke Conference detailed analyses supporting the dosing regimen in NTI’s two ongoing Phase 3 studies of Viprinex(TM) (ancrod) for ischemic stroke.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
